Research reportA possible role of RhoA/Rho-kinase in experimental spinal cord injury in rat
Introduction
Secondary injury following traumatic spinal cord injury is induced by activating a number of cellular and molecular changes [9], [11]. These secondary pathophysiological events result in a host of biochemical changes, including impaired spinal cord blood flow, intracellular Ca2+ overload, excess release of excitatory amino acids, free radical formation, apoptosis, immune activation, and altered gene expression [9], [5], [32]. Derangement of the neuronal cytoskeleton is another important pathological consequence of traumatic central nervous systemic injury [10].
The small GTPase RhoA belongs to the Rho subfamily of GTPases within the Ras superfamily. The best characterized members of this subfamily, which include RhoA-E, RhoG, Rac1-2, Cdc42, and TC10, regulate the organization of the actin cytoskeleton, gene expression, and cell proliferation [8], [14], [26]. A specific extracellular signal activates Rho family proteins and directs the organization of a specific type of actin cytoskeleton to induce the characteristic morphological change(s), respectively [25]. Although the effects of Rho GTPases on the organization of the actin cytoskeleton are perhaps still best characterized in fibroblasts, compelling evidence now demonstrates a similar role for these proteins in all eukaryotic cells including neuronal cells [8], [21]. Rho family members are implicated in the regenerative process, regulating growth cone formation, and elongating neurites.
The possible role of RhoA in secondary injury following spinal cord injury was investigated in this study. Based on the study by Hara et al. [9] that reported that Fasudil hydrochloride showed effectiveness in promoting neurological recovery after traumatic spinal cord injury, we hypothesize that RhoA and its downstream Rho-kinase α, β associated pathway participate in the secondary injury of the injured spinal cord. The spatiotemporal expression of RhoA mRNA and protein expressions, and the effects of RhoA (C3), Rho-kinase (Y-27632), and protein kinase (Fasudil) inhibitors on motor recovery were evaluated.
Section snippets
Materials and methods
All animal experiments were performed in accordance with the guidelines of the National Institutes of Health (NIH) and were approved by the University of Mississippi Medical Center Institutional Standing Committee on Animals.
RhoA mRNA expression in the spinal cord
The competitive RT-PCR assay was used to measure RhoA mRNA collected from the spinal cords of the control group and the rats sacrificed at 1 h, 3 h, 1 day, 3 days, 1 week, and 3 weeks after injury. The expression level of RhoA mRNA (molecules/μg total mRNA) was very low in the uninjured spinal cords and decreased slightly at 1 h after injury. The level of RhoA mRNA expression increased slightly in the injured cords during the period 1–3 days after injury, and values of expression levels peaked
Discussion
In the present study, we have demonstrated the following: (1) the weight-drop method we used created a spinal cord injury model that clinically and histologically resembles the weight-drop models reported by other investigators. (2) RhoA mRNA was highly expressed in contused spinal cord samples taken 1 week post-injury when compared to the samples collected from the control group. (3) The RhoA protein expression directly and significantly increased in contused spinal cords, especially with
Acknowledgements
This work was partially supported by a grant from the American Heart Association National Grant-in-Aid, and a grant from the American Heart Association Bugher Foundation Award for the Investigation of Stroke to J.H.Z.
References (33)
- et al.
The effect of active serum albumin on PC12 cells: II. Intracellular Ca2+ transients and their role in neurite retraction
Brain Res. Mol. Brain Res.
(1992) - et al.
p160 RhoA-binding kinase ROKalpha induces neurite retraction
J. Biol. Chem.
(1998) - et al.
Rho family GTP-binding proteins in growth cone signalling
Curr. Opin. Neurobiol.
(1997) - et al.
Age-related RhoA expression in blood vessels of rats
Mech. Ageing Dev.
(2001) - et al.
Lysophosphatidic acid: G-protein signalling and cellular responses
Curr. Opin. Cell Biol.
(1997) - et al.
Clostridium botulinum C3 ADP-ribosyltransferase gene. Cloning, sequencing, and expression of a functional protein in Escherichia coli
J. Biol. Chem.
(1991) - et al.
Regulation of astrocyte morphology by RhoA and lysophosphatidic acid
Exp. Cell Res.
(1998) - et al.
Pharmacological profile of hydroxy fasudil as a selective rho kinase inhibitor on ischemic brain damage
Life Sci.
(2001) - et al.
Rho as a regulator of the cytoskeleton
Trends Biochem. Sci.
(1995) - et al.
Myosin II activation promotes neurite retraction during the action of Rho and Rho-kinase
Genes Cells
(1998)
A sensitive and reliable locomotor rating scale for open field testing in rats
J. Neurotrauma
The effects of methylprednisolone and the ganglioside GM1 on acute spinal cord injury in rats
J. Neurosurg.
Efficacy of a new neuroprotective agent, gacyclidine, in a model of rat spinal cord injury
J. Neurotrauma
Identification of a novel, putative Rho-specific GDP/GTP exchange factor and a RhoA-binding protein: control of neuronal morphology
J. Cell Biol.
A monitored contusion model of spinal cord injury in the rat
J. Neurotrauma
Rho GTPases and the actin cytoskeleton
Science
Cited by (99)
Mechanisms and repair strategies for white matter degeneration in CNS injury and diseases
2021, Biochimica et Biophysica Acta - Molecular Basis of DiseaseExploring the potential of RhoA inhibitors to improve exercise-recoverable spinal cord injury: A systematic review and meta-analysis
2021, Journal of Chemical NeuroanatomyTowards axonal regeneration and neuroprotection in glaucoma: Rho kinase inhibitors as promising therapeutics
2015, Progress in NeurobiologyChondroitin sulfate proteoglycans: Key modulators in the developing and pathologic central nervous system
2015, Experimental NeurologyCitation Excerpt :Interestingly, RhoA inhibition with C3 exoenzyme has been shown to reduce cell death following SCI in rodents demonstrating the potential neuroprotective benefits of RhoA inhibition (Dubreuil et al., 2003). Cell penetration with C3 exoenzyme is very low, and as a result has yielded varying results in SCI models (Dergham et al., 2002; Dubreuil et al., 2003; Fournier et al., 2003; Sung et al., 2003). Ba-210 (trademarked as Cethrin) is a recombinant engineered variant of C3 exoenzyme that can readily cross the dura of the spinal cord and has shown promising effects in rodent SCI models, however, its role in blocking CSPGs effects have not been tested (Lord-Fontaine et al., 2008).